Amylyx Pharmaceuticals, Inc. (AMLX), a Massachusetts-based biopharmaceutical company, has announced the pricing of an underwritten public offering. The offering involves approximately 17.1 million shares of common stock, priced at $3.50 per share, and is anticipated to generate roughly $60 million.
The proceeds from this offering, combined with existing funds, are allocated for various strategic objectives, including supporting commercialization efforts, advancing pipeline development, providing working capital, and addressing general corporate purposes.
Furthermore, the company intends to provide the underwriters with a 30-day option to purchase up to an additional 2.58 million shares at the same price, excluding underwriting fees.
